The present invention relates to a method for treating a side effect caused by bacillus Calmette-Guérin (BCG) perfusion therapy for bladder cancer. The method includes: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising Gentiana scabra, Scutellariae Radix, Gardeniae Fructus, Angelicae Sinensis Radix, Rehmanniae radix, Akebiae Caulis, Bupleurum chinense, Plantaginis Semen, Atractylodes lancea, Rhizoma alismatis, and Glycyrrhiza uralensis.

The present invention relates to a method for treating a side effect caused by bacillus Calmette-Guérin (BCG) perfusion therapy for bladder cancer. The method includes: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising Gentiana scabra, Scutellariae Radix, Gardeniae Fructus, Angelicae Sinensis Radix, Rehmanniae radix, Akebiae Caulis, Bupleurum chinense, Plantaginis Semen, Atractylodes lancea, Rhizoma alismatis, and Glycyrrhiza uralensis.

In an aspect, the present disclosure provides a method for producing an extract composition by which polyphenols such as apigenin and/or essential oil components such as spiro-ether can be efficiently extracted from harvested herbaceous plants.

An aspect of the present disclosure is directed to a method for producing an extract composition, including processes (1) and (2) below: (1) applying an oxidative stress to a harvested herbaceous plant and preserving it; and (2) obtaining an extract from the herbaceous plant that has undergone the process (1).

The present invention relates to a drug for treating leukopenia, its preparation method and use thereof. The drug of the invention is prepared from 200-30 parts by weight of Folium Epimedii, 100-160 parts by weight of Fructus Psoraleae, 60-120 parts by weight of Radix Aconiti Lateralis Preparata (Processed), 200-300 parts by weight of Fructus Lycii, 200-300 parts by weight of Radix Astragali, 200-300 parts by weight of Caulis Spatholobi, 200-300 parts by weight of Radix Rubiae, 100-160 parts by weight of Radix Angelicae Sinensis, 200-300 parts by weight of Rhizoma Phragmitis, 100-160 parts by weight of Radix Ophiopogonis and 100-160 parts by weight of Radix et Rhizoma Glycyrrhizae. The drug of the invention comprises chemical substances with weight ratios as follows: Leucine:guanosine:psoralenoside:isopsoralenoside:calycosin-7-glucoside:liquiritin:icariin A:1,3-dihydroxyl-2-hydroxymethylanthraquinone:epimedin A:epimedin B:epimedin C:icariin:1,3,6-trihydroxy-2-methylanthraquinone:glycyrrhizic acid=(0.13-0.27):(0.04-0.11):(0.11-0.34):(0.09-0.34):(0.05-0.11):(0.16-0.26):(0.09-0.12):(0.17-0.35):(0.11-0.16):(0.17-0.26):(0.49-0.59):1.00:(0.16-0.24):(0.08-0.14).

The present invention relates to a drug for treating leukopenia, its preparation method and use thereof. The drug of the invention is prepared from 200-30 parts by weight of Folium Epimedii, 100-160 parts by weight of Fructus Psoraleae, 60-120 parts by weight of Radix Aconiti Lateralis Preparata (Processed), 200-300 parts by weight of Fructus Lycii, 200-300 parts by weight of Radix Astragali, 200-300 parts by weight of Caulis Spatholobi, 200-300 parts by weight of Radix Rubiae, 100-160 parts by weight of Radix Angelicae Sinensis, 200-300 parts by weight of Rhizoma Phragmitis, 100-160 parts by weight of Radix Ophiopogonis and 100-160 parts by weight of Radix et Rhizoma Glycyrrhizae. The drug of the invention comprises chemical substances with weight ratios as follows: Leucine:guanosine:psoralenoside:isopsoralenoside:calycosin-7-glucoside:liquiritin:icariin A:1,3-dihydroxyl-2-hydroxymethylanthraquinone:epimedin A:epimedin B:epimedin C:icariin:1,3,6-trihydroxy-2-methylanthraquinone:glycyrrhizic acid=(0.13-0.27):(0.04-0.11):(0.11-0.34):(0.09-0.34):(0.05-0.11):(0.16-0.26):(0.09-0.12):(0.17-0.35):(0.11-0.16):(0.17-0.26):(0.49-0.59):1.00:(0.16-0.24):(0.08-0.14).

A composition of plant ingredients and a composition of herbs are introduced. The composition of plant ingredients and the composition of herbs respectively include Camellia, lotus seedpod of Nelumbo nucifera, Eucommia ulmoides Oliver, Glechoma hederacea and Angelica keiskei. The composition of plant ingredients and the composition of herbs can inhibit coronavirus infection in host cells.

A composition of plant ingredients and a composition of herbs are introduced. The composition of plant ingredients and the composition of herbs respectively include Camellia, lotus seedpod of Nelumbo nucifera, Eucommia ulmoides Oliver, Glechoma hederacea and Angelica keiskei. The composition of plant ingredients and the composition of herbs can inhibit coronavirus infection in host cells.

Provided are an antithrombotic composition (platelet aggregation inhibitor) comprising an Angelica gigas Nakai extract and a pharmaceutical composition for prevention and/or treatment of vascular disease, which comprises an Angelica gigas Nakai extract. The compositions are characterized in that they do not cause a gastrointestinal disorder.

Provided are an antithrombotic composition (platelet aggregation inhibitor) comprising an Angelica gigas Nakai extract and a pharmaceutical composition for prevention and/or treatment of vascular disease, which comprises an Angelica gigas Nakai extract. The compositions are characterized in that they do not cause a gastrointestinal disorder.

A composition for alleviating or treating asthma is proposed. A composition for alleviating or treating asthma contains, as an active ingredient, a concentrate obtained by distilling an extract obtained by extracting a herb medicine complex containing dried Rehmanniae radix, Cyperus rotundus L., Paeonia lactiflora Pall., Zingiber officinale Roscoe, Angelica gigas root, Carthamus tinctorius L., and Glycyrrhiza uralensis Fisch., using an extraction solvent, and can be provided in the form of an oriental pharmacopuncture solution or an injection.